# A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

> **NCT07460375** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **LigaChem Biosciences, Inc.** · enrollment: 191 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** LCB02A

## Key facts

- **NCT ID:** NCT07460375
- **Lead sponsor:** LigaChem Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2030-02
- **Final completion:** 2030-08
- **Target enrollment:** 191 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07460375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07460375, "A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07460375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*